Zusammenfassung
Die Chorea Huntington (HD) ist eine autosomal-dominant vererbte und progressiv-degenerative
Erkrankung des Zentralnervensystems. Klinisch imponieren vor allem einschießende,
irreguläre (choreiforme) Hyperkinesen am ganzen Körper, Grimassieren und Artikulationsstörungen.
Psychopathologische Veränderungen treten sehr häufig auf und gehen den typischen motorischen
Symptomen teilweise um Jahre voraus. Wir schildern hier die Behandlung einer Patientin,
bei welcher die psychopathologischen und kognitiven Auffälligkeiten ganz im Vordergrund
standen, mit dem atypischen Antipsychotikum Amisulprid. Der klinische Verlauf wird
beschrieben und die Frühdiagnostik unter besonderer Berücksichtigung neuropsychologischer
Aspekte diskutiert.
Abstract
Huntington's disease is a hereditary and progressive disease of the central nervous
system. Sudden and irregular hyperkinesias are prominent. Psychopathological findings
are very frequent and often proceed the decline of motor functions for years. Almost
all the patients develop a dementia in later stages of the illness. This case study
shows the treatment of a patient with Huntington's disease, verified by genetic analysis,
with the atypical antipsychotic drug amisulpride. In this case the psychiatric disturbances
and cognitive impairments were the only signs of the disease. The treatment showed
an impressive improvement. Neuropsychological aspects of the disease are discussed.
Literatur
1
Hofmann N.
Understanding the neuropsychiatric symptoms of Huntington's disease.
J Neurosci Nurs.
1999;
31
309-313
2
Caine E D, Hunt R D, Weingartner H, Ebert M H.
Huntington's dementia. Clinical and neuropsychological features.
Arch Gen Psychiatry.
1978;
35
377-384
3
Foroud T, Siemers E, Kleindorfer D. et al .
Cognitive scores in carriers of Huntington's disease gene compared to noncarriers.
Ann Neurol.
1995;
37
657-664
4
Dose M, Lange H W.
The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndroms.
Pharmacopsychiatry.
2000;
33
19-27
5
van Vugt J P, Siesling S, Vergeer M, van der Velde E A, Roos R A.
Clozapine versus placebo in Huntington's disease: a double blind randomised comparative
study.
J Neurol Neurosurg Psychiatry.
1997;
63
35-39
6
Leroi I, Michalon M.
Treatment of the psychiatric manifestations of Huntington's disease: a review of the
literature.
Can J Psychiatry.
1998;
43
933-940
7
Madhusoodanan S, Brenner R, Moise D, Sindagi J, Brafman I.
Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study.
Ann Clin Psychiatry.
1998;
10
117-120
8
Aylward E H, Codori A M, Rosenblatt A. et al .
Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease.
Mov Disord.
2000;
15
552-560
9
Aylward E H, Anderson N B, Bylsma F W. et al .
Frontal lobe volume in patients with Huntington's disease.
Neurology.
1998;
50
252-258
10
Mendez M F.
Huntington's disease: update and review of neuropsychiatric aspects.
Int J Psychiatry Med.
1994;
24
189-208
11
Kirkwood S C, Siemers E, Stout J C. et al .
Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene
carriers.
Arch Neurol.
1999;
56
563-568
12
Walker E, Lewis N, Loewy R, Palyo S.
Motor dysfunction and risk for schizophrenia.
Dev Psychopathol.
1999;
11
509-523
13
Lawrence A D, Hodges J R, Rosser A E. et al .
Evidence for specific cognitive deficits in preclinical Huntington's disease.
Brain.
1998;
121
1329-1341
14
Manschreck T C, Maher B A, Candela S F, Redmond D, Yurgelun-Todd D, Tsuang M.
Impaired verbal memory is associated with impaired motor performance in schizophrenia:
relationship to brain structure.
Schizophr Res.
2000;
43
21-32
15
Sprengelmeyer R, Lange H, Homberg V.
The pattern of attentional deficits in Huntington's disease.
Brain.
1995;
118
145-152
16
Jason G W, Suchowersky O, Pajurkova E M. et al .
Cognitive manifestations of Huntington disease in relation to genetic structure and
clinical onset.
Arch Neurol.
1997;
54
1081-1088
17
Hanes K R, Andrewes D G, Pantelis C, Chiu E.
Subcortical dysfunction in schizophrenia: a comparison with Parkinson's disease and
Huntington's disease.
Schizophr Res.
1996;
19
121-128
18
Hanes K R, Andrewes D G, Pantelis C.
Cognitive flexibility and complex integration in Parkinson's disease, Huntington's
disease, and schizophrenia.
J Int Neuropsychol Soc.
1995;
1
545-553
Priv.-Doz. Dr. Dieter F. Braus
NMR-Forschung am Zentralinstitut für Seelische Gesundheit
Postfach 122120
68072 Mannheim
Email: dfbraus@zi-mannheim.de